Robotic Biopsy Devices Market is expected to reach a valuation of around US$ 1.1 Billion by 2032 | CAGR 9.4%

The global Robotic Biopsy Devices Market was valued at US$ 386.4 million in 2021 and is expected to grow at a CAGR of 9.4% during the forecast period (2022-2032). Robotic biopsy systems are the global market leader, with a market share of approximately 59.8% in 2021. By the end of 2032, the global robotic biopsy devices market is expected to be worth approximately US$ 1.1 billion.

One of the most significant cutting-edge technologies in neurosurgery is robot-assisted biopsy for brain tumors. A robot-assisted biopsy is used to increase the safety and effectiveness of biopsy technique, which is highly desired when organizing the management of tumor pathology.

The main objective of this cutting-edge technology is to add safety equipment to the modern neurosurgery operative inventory so that it can methodically improve the precision and accuracy in operation theaters, which is not otherwise conceivable. Additionally, robotic biopsy makes the thorough preoperative process easier than other types.

Get a PDF Sample with the Latest Market Insights @

The market for robotic biopsy devices is anticipated to grow at a fast pace over the projected years due to rising need for safe and effective minimally invasive procedures and the growing use of automated systems in the healthcare sector. It can be further attributed to rapid transformation of conventional healthcare systems to integrated digital technology.

Key Takeaways: Robotic Biopsy Devices Market

  • By product, the systems segment is expected to showcase high growth at a CAGR of 4% by the end of 2032.
  • By application, the brain biopsy category is leading the global robotic biopsy devices market and is projected to exhibit a CAGR of 3% during the forecast period.
  • By end user, hospitals held around 5% of the global robotic biopsy devices market share in 2021.
  • The U.S. currently dominates the North America robotic biopsy devices market and it had generated a share of about 8% in 2021.
  • The U.K. is set to hold a share of nearly 2% in the global robotic biopsy devices market during the assessment period.

“Increasing use of automated technologies for surgical procedures and growing global burden of chronic diseases are expected to drive sales of robotic biopsy devices,” says an analyst of Future Market Insights.

Ask Us Your Questions About This Report @

Competition Landscape: Robotic Biopsy Devices Market

The market for robotic biopsy devices is oligopolistic, with the presence of a few established manufacturers. Product range of every player in the market varies as per the competitors’ licensed novel devices with unique applications. Key players are striving to gain regulatory authorizations for creating new medical devices, generating high product sales, and initiating marketing purposes.

  • In October 2021, Medtronic reported that the Hugo robotic-assisted surgery (RAS) system had been granted the CE (Conformité Européenne) Mark, allowing for sales of the system across Europe.

Key Companies Profiled:

  • Medtronic
  • Renishaw plc
  • iSYS Medizintechnik GmbH
  • Mazor Robotics
  • Biobot Surgical Pte Ltd
  • Medrobotics
  • Medtech SA

Ask the Analyst for Report Customization and Explore TOC & List of Figures @

Robotic Biopsy Devices Market Outlook by Category

By Product:

  • Systems
  • Instrument & Accessories

By Application:

  • Brain Biopsy
  • Lung Biopsy
  • Prostate biopsy
  • Others

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Academic & Research Institutes

About Future Market Insights (FMI) 

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.


Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
Browse All Reports:

Leave a comment

Your email address will not be published. Required fields are marked *